![]() |
|
|
Vol. 293, Issue 3, 861-869, June 2000
Department of Pharmacy Practice and Science and the Center for
Toxicology, College of Pharmacy, The University of Arizona, Tucson,
Arizona
The advent of combinatorial chemistry has led to a deluge of new
chemical entities whose metabolic pathways need to be determined. A
significant issue involves determination of the ability of new agents
to inhibit the metabolism of existing drugs as well as its own
susceptibility for altered metabolism. There is need to estimate the
enzyme inhibition parameters and mechanism or mechanisms of inhibition
with minimal experimental effort. We examined a minimal experimental
design for obtaining reliable estimates of Ki (and Vmax and
Km). Simulations have been applied to a
variety of experimental scenarios. The least experimentally demanding case involved three substrate concentrations, [S], for the control and one substrate-inhibitor pair, [S]-[I]. The control and
inhibitor data (with 20% coefficient of variance random error) were
simultaneously fit to the full nonlinear competitive inhibition
equation [simultaneous nonlinear regression (SNLR)]. Excellent
estimates of the correct kinetic parameters were obtained. This
approach is clearly limited by the a prior assumption of mechanism.
Further simulations determined whether SNLR would permit assessment of
the inhibition mechanism (competitive or noncompetitive). The minimal
design examined three [S] (control) and three [S]-[I] pairs. This
design was successful in identifying the correct model for 98 of 100 data sets (20% coefficient of variance random error). SNLR analysis of
metabolite formation rate versus [S] permits a dramatic reduction in
experimental effort while providing reliable estimates of
Ki, Km, and
Vmax along with an estimation of the
mechanism of inhibition. The accuracy of the parameter estimates will
be affected by the experimental variability of the system under investigation.
This article has been cited by other articles:
![]() |
W. Kang and M. Weiss Digoxin Uptake, Receptor Heterogeneity, and Inotropic Response in the Isolated Rat Heart: A Comprehensive Kinetic Model J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 577 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Weiss and W. Kang P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 688 - 694. [Abstract] [Full Text] [PDF] |
||||